These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 30453348

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Characterization of a recombinant factor IX molecule fused to coagulation factor XIII-B subunit.
    Desage S, Leuci A, Enjolras N, Holle LA, Singh S, Delavenne X, Wolberg AS, Biswas A, Dargaud Y.
    Haemophilia; 2023 Nov; 29(6):1483-1489. PubMed ID: 37707428
    [Abstract] [Full Text] [Related]

  • 3. Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice.
    Toby GG, Liu T, Buyue Y, Zhang X, Bitonti AJ, Pierce GF, Sommer JM, Jiang H, Peters RT.
    PLoS One; 2016 Nov; 11(2):e0148255. PubMed ID: 26840952
    [Abstract] [Full Text] [Related]

  • 4. Half-life extension through albumin fusion technologies.
    Schulte S.
    Thromb Res; 2009 Dec; 124 Suppl 2():S6-8. PubMed ID: 20109653
    [Abstract] [Full Text] [Related]

  • 5. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX.
    Metzner HJ, Weimer T, Kronthaler U, Lang W, Schulte S.
    Thromb Haemost; 2009 Oct; 102(4):634-44. PubMed ID: 19806248
    [Abstract] [Full Text] [Related]

  • 6. Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs.
    Nolte MW, Nichols TC, Mueller-Cohrs J, Merricks EP, Pragst I, Zollner S, Dickneite G.
    J Thromb Haemost; 2012 Aug; 10(8):1591-9. PubMed ID: 22726310
    [Abstract] [Full Text] [Related]

  • 7. Prolonged activity of factor IX as a monomeric Fc fusion protein.
    Peters RT, Low SC, Kamphaus GD, Dumont JA, Amari JV, Lu Q, Zarbis-Papastoitsis G, Reidy TJ, Merricks EP, Nichols TC, Bitonti AJ.
    Blood; 2010 Mar 11; 115(10):2057-64. PubMed ID: 20056791
    [Abstract] [Full Text] [Related]

  • 8. Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity.
    Perot E, Enjolras N, Le Quellec S, Indalecio A, Girard J, Negrier C, Dargaud Y.
    Thromb Res; 2015 May 11; 135(5):1017-24. PubMed ID: 25795563
    [Abstract] [Full Text] [Related]

  • 9. Clinical, pharmacokinetic and economic analysis of the first switch to an extended half-life factor IX (albutrepenonacog alfa, rFIX-FP) in Spain.
    Rodríguez López M, Megías Vericat JE, Albo López C, Bonanad S.
    BMJ Case Rep; 2020 Oct 13; 13(10):. PubMed ID: 33051199
    [Abstract] [Full Text] [Related]

  • 10. Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study.
    Powell JS, Apte S, Chambost H, Hermans C, Jackson S, Josephson NC, Mahlangu JN, Ozelo MC, Peerlinck K, Pasi J, Perry D, Ragni MV, Wang X, Jiang H, Li S, Cristiano LM, Innes A, Nugent K, Brennan A, Luk A, Allen G, Pierce GF, Robinson B.
    Br J Haematol; 2015 Jan 13; 168(1):124-34. PubMed ID: 25208598
    [Abstract] [Full Text] [Related]

  • 11. Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates.
    Iorio A, Fischer K, Blanchette V, Rangarajan S, Young G, Morfini M, Pharmacokinetic (PK) Expert Working Group of the International Prophylaxis Study Group (the IPSG).
    Thromb Haemost; 2017 Jun 02; 117(6):1023-1030. PubMed ID: 28357444
    [Abstract] [Full Text] [Related]

  • 12. In vivo efficacy of human recombinant factor IX produced by the human hepatoma cell line HuH-7.
    Enjolras N, Perot E, Le Quellec S, Indalecio A, Girard J, Negrier C, Dargaud Y.
    Haemophilia; 2015 Jul 02; 21(4):e317-21. PubMed ID: 25981983
    [Abstract] [Full Text] [Related]

  • 13. Discovery of An Orally Effective Factor IX-Transferrin Fusion Protein for Hemophilia B.
    Xie C, Wang Z, Su Y, Wang J, Shen WC.
    Int J Mol Sci; 2019 Dec 18; 21(1):. PubMed ID: 31861459
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients.
    Collins PW, Quon DVK, Makris M, Chowdary P, Kempton CL, Apte SJ, Ramanan MV, Hay CRM, Drobic B, Hua Y, Babinchak TJ, Gomperts ED.
    Haemophilia; 2018 Jan 18; 24(1):104-112. PubMed ID: 28833808
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis.
    Hermans C, Marino R, Lambert C, Mangles S, Sommerer P, Rives V, Maro G, Malcangi G.
    Adv Ther; 2020 Jun 18; 37(6):2988-2998. PubMed ID: 32333327
    [Abstract] [Full Text] [Related]

  • 18. Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B.
    Brinkhous KM, Sigman JL, Read MS, Stewart PF, McCarthy KP, Timony GA, Leppanen SD, Rup BJ, Keith JC, Garzone PD, Schaub RG.
    Blood; 1996 Oct 01; 88(7):2603-10. PubMed ID: 8839853
    [Abstract] [Full Text] [Related]

  • 19. Emerging drugs for hemophilia B.
    Mannucci PM, Franchini M.
    Expert Opin Emerg Drugs; 2014 Sep 01; 19(3):407-14. PubMed ID: 25098797
    [Abstract] [Full Text] [Related]

  • 20. A new population pharmacokinetic model for recombinant factor IX-Fc fusion concentrate including young children with haemophilia B.
    Koopman SF, Goedhart TMHJ, Bukkems LH, Mulders TM, Leebeek FWG, Fijnvandraat K, Coppens M, Mathias M, Collins PW, Tait RC, Bagot CN, Curry N, Payne J, Chowdary P, Cnossen MH, Mathôt RAA, OPTI-CLOT study group and SYMPHONY consortium.
    Br J Clin Pharmacol; 2024 Jan 01; 90(1):220-231. PubMed ID: 37567779
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.